CA
NZ
UK
AU
IND
US
Aurinia Pharmaceuticals Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission, disclosing net income of $37.4 million for the second quarter and $71.8 million for the first half of 2026.
CRA International, Inc. filed a Form 8-K with the SEC on August 6, 2026, disclosing financial results for its fiscal quarter ended July 4, 2026, a quarterly cash dividend declaration, and an increase and extension to its existing credit facility.
CRA International, Inc. filed its Form 10-Q for the fiscal quarter ended July 4, 2026 with the U.S. Securities and Exchange Commission, reporting second-quarter and year-to-date financial results for fiscal 2026.
Oyster Enterprises II Acquisition Corp, a Cayman Islands exempted special purpose acquisition company listed on The Nasdaq Stock Market LLC, filed its quarterly report on Form 10-Q for the period ended June 30, 2026 on August 6, 2026.
Praxis Precision Medicine, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 6, 2026, covering the quarterly period ended June 30, 2026.
Valaris Limited filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 6, 2026, covering the quarterly period ended June 30, 2026.
CG Oncology, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on August 6, 2026, covering the three- and six-month periods ended June 30, 2026.
Priority Technology Holdings, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the Securities and Exchange Commission, reporting second-quarter and first-half financial results including revenues, net income, and balance sheet positions.
Privia Health Group, Inc. filed its quarterly report on Form 10-Q with the SEC for the period ended June 30, 2026, disclosing condensed consolidated financial statements and related management discussion.
CG Oncology, Inc. filed a current report on August 6, 2026, announcing second-quarter financial results for the period ended June 30, 2026, and disclosing an amendment to its at-the-market equity offering program that adds $500.0 million in available shares for sale.
Please wait processing your request...